THOUSAND OAKS, Calif., March 2, 2015, Amgen - today announced that the Neulasta® (pegfilgrastim) Delivery Kit is now available in the United States (U.S.). The Neulasta Delivery Kit includes a specially designed single-use prefilled syringe co-packaged with the new On-body Injector for Neulasta. Neulasta Delivery Kit is an on-body injector, which can improve conditions for chemo patients without them having to return to hospital.
Medical researchers are constantly looking for ways to administer treatments to suffering patients in less painful and inconvenient ways. We recently wrote about the temporary tattoo which could provide a non-invasive alternative to diabetics’ daily blood tests. The Neulasta Delivery Kit is another such device which could improve treatment conditions — it is an on-body injector that can help ward off some of the side effects of chemotherapy by delivering pegfilgrastim to patients the day after their treatment starts.
One of the most common side effects of chemo treatments is neurtropenia — or low white blood cell count. Neulasta can help boost white blood cells if delivered exactly 27 hours after chemotherapy begins, but despite having been available for 12 years, often patients don’t receive their prescribed dosage because their treatment has made them unable to return to hospital for the injection.
The Neulasta Delivery Kit solves this problem by enabling patients to receive the treatment from the comfort of their own home.
After the chemotherapy session, clinicians can fill and activate the syringe with the correct dosage. They then apply the on-body injector to the patient and it automatically activates the following day, providing the patient with the medicine they need without requiring them to return to hospital for the shot.
Neulasta Delivery Kit Provides Administration Option for Patients who may not Otherwise Need to Return to Clinic or Hospital the day After Chemotherapy
The Neulasta Delivery Kit will enable the healthcare provider (HCP) to initiate administration of Neulasta on the same day as cytotoxic chemotherapy – with delivery of the patient's full dose of Neulasta the day following chemotherapy administration, consistent with the Neulasta prescribing information (PI).1,2
One of the most common side effects of myelosuppressive chemotherapy is a low white blood cell count, or neutropenia. Febrile neutropenia (neutropenia with fever) is a medical emergency and is associated with an increased risk of hospitalization and use of IV anti-infective drugs.
For more information about Neulasta, visit and www.NeulastaHCP.com.
Note: Articles and Publications Resources: Get Seen - Get Screened, Mayo Clinic, Colon Cancer Alliance, American Cancer Institute, National Cancer Institute, and others. We hope to inspire, educate and empowered you…One Day at a Time!